First Financial Bankshares Inc raised its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 245.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,069 shares of the company’s stock after acquiring an additional 10,000 shares during the quarter. First Financial Bankshares Inc’s holdings in AbbVie were worth $3,680,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently modified their holdings of the company. Fisher Asset Management LLC raised its holdings in AbbVie by 252.6% in the 3rd quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock worth $8,760,498,000 after purchasing an additional 23,991,451 shares during the period. Corient Private Wealth LP purchased a new position in AbbVie during the second quarter valued at $559,736,000. Legal & General Group Plc purchased a new position in AbbVie during the second quarter valued at $2,905,952,000. Jupiter Topco LLC bought a new stake in AbbVie during the second quarter valued at about $1,560,354,000. Finally, Canada Pension Plan Investment Board bought a new stake in AbbVie during the second quarter valued at about $817,473,000. Institutional investors own 70.23% of the company’s stock.
AbbVie Price Performance
Shares of ABBV stock opened at $294.18 on Tuesday. AbbVie Inc. has a one year low of $190.75 and a one year high of $302.93. The company’s fifty day moving average price is $276.27 and its 200-day moving average price is $241.28. The company has a market capitalization of $520.00 billion, a price-to-earnings ratio of 50.63, a PEG ratio of 1.34 and a beta of 0.20.
AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping the consensus estimate of $3.73 by $0.09. The company had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. AbbVie’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.86 EPS. Equities research analysts expect that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.
AbbVie Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be issued a dividend of $1.82 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Friday, January 15th. AbbVie’s payout ratio is 125.30%.
Insider Activity at AbbVie
In other news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $293.60, for a total value of $11,925,738.40. Following the transaction, the executive vice president directly owned 83,171 shares in the company, valued at $24,419,005.60. The trade was a 32.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is owned by insiders.
Analysts Set New Price Targets
ABBV has been the subject of a number of analyst reports. Cantor Fitzgerald upped their price target on AbbVie from $290.00 to $325.00 and gave the stock an “overweight” rating in a research report on Monday, November 2nd. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and lifted their price objective for the company from $235.00 to $300.00 in a research report on Thursday, August 13th. The Goldman Sachs Group boosted their price objective on AbbVie from $258.00 to $294.00 and gave the company a “neutral” rating in a research note on Friday, October 23rd. BNP Paribas Exane boosted their price objective on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Finally, UBS Group increased their target price on shares of AbbVie from $275.00 to $295.00 and gave the stock a “neutral” rating in a report on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $297.85.
Read Our Latest Report on ABBV
About AbbVie
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Further Reading
- Five stocks we like better than AbbVie
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
